摘要
目的探讨匹伐他汀联合二甲双胍对非酒精性脂肪性肝病(NAFLD)患者血脂和肝功能的影响,以期为临床治疗提供参考。方法本研究选取2018年3月—2020年3月在河南省郑州市金水区总医院就诊的108例NAFLD患者为研究对象。采用随机数字表法,将患者分为观察组与对照组,每组54例。对照组患者给予二甲双胍治疗,观察组患者在对照组基础上加用匹伐他汀治疗。治疗结束时,比较2组患者治疗效果。比较2组患者治疗前后三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白(HDL-C)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(γ-GT)水平。比较2组患者治疗期间不良反应发生情况。结果2组患者治疗总有效率比较,差异无统计学意义(P>0.05)。治疗前,2组患者TG、HDL-C和LDL-C水平比较,差异无统计学意义(P>0.05)。治疗后,2组患者TG和LDL-C水平均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组患者HDL-C水平高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。治疗前,2组患者ALT、AST和γ-GT水平比较,差异无统计学意义(P>0.05)。治疗后,2组患者ALT、AST和γ-GT水平均高于治疗前,但观察组低于对照组,差异均有统计学意义(P<0.05)。2组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论匹伐他汀联合二甲双胍对NAFLD的治疗效果较好,可显著改善患者血脂水平,对患者肝功能损害较小,值得临床推广应用。
Objective This paper aims to investigate the effects of pitavastatin combined with metformin on blood lipid and liver function in patients with nonalcoholic fatty liver disease(NAFLD)to provide evidence for clinical treatment.Methods A total of 108 patients with NAFLD who visited Jinshui General Hospital from March 2018 to March 2020 were selected as the study participants.They were assigned to the observation group and control group by random number table,with 54 cases in each group.Patients in the control group received metformin,and patients in the observation group received pitavastatin on the basis of the control group.At the end of treatment,the treatment effect was compared between the 2 groups.Triacylglycerol(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),alanine aminotransferase(ALT),aspartate aminotransferase(AST),andγ-glutamyl transpeptidase(γ-GT)levels were compared between the two groups before and after treatment.The incidence of adverse reactions during treatment was also compared between the groups.Results There was no significant difference in the overall response rate between the two groups(P>0.05).Before treatment,there was no significant difference in TG,HDL-C,and LDL-C levels between the 2 groups(P>0.05).After treatment,TG and LDL-C levels in the two groups were significantly lower than those before treatment,with the observation group significantly lower than the control group(P<0.05).After treatment,the HDL-C level in the two groups was significantly increased,and the observation group was significantly higher than the control group(P<0.05).Before treatment,there was no significant difference in ALT,AST,andγ-GT levels between the 2 groups(P>0.05).After treatment,ALT,AST,andγ-GT levels in the two groups were significantly increased,while those in the observation group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Pitavastatin combined with metformin demonstrates good therapeutic efficacy on NAFLD,which can markedly improve the blood lipid level and demonstrate less liver function damage.These benefits hold promise for a wider application of this procedure clinically.
作者
汪倩倩
Wang Qianqian(Department of Pharmacy,Jinshui General Hospital,Zhengzhou 450000,China)
出处
《保健医学研究与实践》
2023年第4期17-20,共4页
Health Medicine Research and Practice
